Browsing by author "Folkerd, Elizabeth"
Now showing items 1-10 of 10
-
Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK - A16037).
Banerjee, S; Tovey, H; Bowen, R; Folkerd, E; Kilburn, L; et al. (SAGE PUBLICATIONS LTD, 2020-12-01)BACKGROUND: Recurrent epithelial ovarian cancer (EOC) remains difficult to treat, with an urgent need for more therapy options. Androgens bind to the androgen receptor (AR), commonly expressed in EOC. CYP17 inhibitor ... -
Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.
Simigdala, N; Pancholi, S; Ribas, R; Folkerd, E; Liccardi, G; et al. (SPRINGERNATURE, 2018-08-01)BACKGROUND: Resistance to endocrine therapy remains a major clinical problem in the treatment of oestrogen-receptor positive (ER+) breast cancer. Studies show androgen-receptor (AR) remains present in 80-90% of metastatic ... -
Changes in expression of hormone-regulated and proliferation-associated genes across the menstrual cycle in oestrogen receptor-positive breast cancer
Haynes, BP; Ginsburg, O; Gao, Q; Folkerd, E; Afentakis, M; et al. (SPRINGER, 2020-04-01) -
Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala, N; Gao, Q; Pancholi, S; Roberg-Larsen, H; Zvelebil, M; et al. (BMC, 2016-06-01)BACKGROUND: Therapies targeting estrogenic stimulation in estrogen receptor-positive (ER+) breast cancer (BC) reduce mortality, but resistance remains a major clinical problem. Molecular studies have shown few high-frequency ... -
Circulating Growth and Sex Hormone Levels and Breast Tissue Composition in Young Nulliparous Women.
Denholm, R; De Stavola, BL; Hipwell, JH; Doran, SJ; Holly, JMP; et al. (AMER ASSOC CANCER RESEARCH, 2018-12-01)BACKGROUND: Endogenous hormones are associated with breast cancer risk, but little is known about their role on breast tissue composition, a strong risk predictor. This study aims to investigate the relationship between ... -
Combined effects of endogenous sex hormone levels and mammographic density on postmenopausal breast cancer risk: results from the Breakthrough Generations Study.
Schoemaker, MJ; Folkerd, EJ; Jones, ME; Rae, M; Allen, S; et al. (NATURE PUBLISHING GROUP, 2014-04-02)BACKGROUND: Mammographic density and sex hormone levels are strong risk factors for breast cancer, but it is unclear whether they represent the same aetiological entity or are independent risk factors. METHODS: Within the ... -
Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study.
Johnson, N; Dudbridge, F; Orr, N; Gibson, L; Jones, ME; et al. (BMC, 2014-05-26)INTRODUCTION: We have previously shown that a tag single nucleotide polymorphism (rs10235235), which maps to the CYP3A locus (7q22.1), was associated with a reduction in premenopausal urinary estrone glucuronide levels and ... -
Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer.
Haynes, BP; Ginsburg, O; Gao, Q; Folkerd, E; Afentakis, M; et al. (NATURE PUBLISHING GROUP, 2019-11-15)The major changes in hormone levels that occur through the menstrual cycle have been postulated to affect the expression of hormone-regulated and proliferation-associated genes (PAGs) in premenopausal ER+ breast cancer. ... -
Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy.
Haynes, BP; Ginsburg, O; Gao, Q; Folkerd, E; Afentakis, M; et al. (NATURE PUBLISHING GROUP, 2017-11-27)For premenopausal women with primary ER + breast cancer, oophorectomy (OvX) is an evidence-based cost-effective option and is standard treatment in many countries. However, there is virtually no data describing the effects ... -
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl, S; Turner, NC; Ro, J; Cristofanilli, M; Iwata, H; et al. (WILEY, 2017-09-01)BACKGROUND: The efficacy and safety of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, combined with fulvestrant and goserelin was assessed in premenopausal women with advanced breast cancer (ABC) who had progressed ...